{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:59:08Z","timestamp":1764194348862,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 11118"],"award-info":[{"award-number":["SFB 11118"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s13300-018-0551-9","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:21:06Z","timestamp":1546978866000},"page":"229-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis"],"prefix":"10.1007","volume":"10","author":[{"given":"Sergio","family":"Modafferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Ries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus. P.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-0848","authenticated-orcid":false,"given":"Verena","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","volume":"128","author":"K Ogurtsova","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40\u201350.","journal-title":"Diabetes Res Clin Pract"},{"key":"551_CR2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2011.861","volume":"305","author":"IH de Boer","year":"2011","unstructured":"de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532\u20139.","journal-title":"JAMA"},{"key":"551_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10557-017-6755-9","volume":"31","author":"C Magee","year":"2017","unstructured":"Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017;31:579\u201392.","journal-title":"Cardiovasc Drugs Ther"},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2015.05.001","volume":"66","author":"R Saran","year":"2015","unstructured":"Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015;66:S1\u2013305.","journal-title":"Am J Kidney Dis"},{"key":"551_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/ndt\/gfu411","volume":"31","author":"GC Chan","year":"2016","unstructured":"Chan GC, Tang SC. Diabetic nephropathy: landmark clinical trials and tribulations. Nephrol Dial Transplant. 2016;31:359\u201368.","journal-title":"Nephrol Dial Transplant"},{"key":"551_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrneph.2010.55","volume":"6","author":"S Tonna","year":"2010","unstructured":"Tonna S, El-Osta A, Cooper ME, Tikellis C. Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol. 2010;6:332\u201341.","journal-title":"Nat Rev Nephrol"},{"key":"551_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"551_CR8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jama.284.10.1290","volume":"284","author":"GH Guyatt","year":"2000","unstructured":"Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users\u2019 guides to the medical literature: 25. Evidence-based medicine: principles for applying the Users\u2019 Guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290\u20136.","journal-title":"JAMA"},{"key":"551_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2016.14668","volume":"316","author":"KL Hudson","year":"2016","unstructured":"Hudson KL, Lauer MS, Collins FS. Toward a new era of trust and transparency in clinical trials. JAMA. 2016;316:1353\u20134.","journal-title":"JAMA"},{"key":"551_CR10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/ncpneuro0618","volume":"3","author":"RT Johnson","year":"2007","unstructured":"Johnson RT, Dickersin K. Publication bias against negative results from clinical trials: three of the seven deadly sins. Nat Clin Pract Neurol. 2007;3:590\u20131.","journal-title":"Nat Clin Pract Neurol"},{"key":"551_CR11","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","volume":"375","author":"DA Zarin","year":"2016","unstructured":"Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov\u2014the final rule. N Engl J Med. 2016;375:1998\u20132004.","journal-title":"N Engl J Med"},{"key":"551_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1053\/j.ajkd.2011.06.020","volume":"58","author":"EJ Lewis","year":"2011","unstructured":"Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58:729\u201336.","journal-title":"Am J Kidney Dis"},{"key":"551_CR13","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978\u201386.","journal-title":"Diabetologia"},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.2337\/db12-1512","volume":"62","author":"EJ Weil","year":"2013","unstructured":"Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013;62:3224\u201331.","journal-title":"Diabetes"},{"key":"551_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2337\/db09-1630","volume":"60","author":"C Ott","year":"2011","unstructured":"Ott C, Schneider MP, Delles C, Schlaich MP, Schmieder RE. Reduction in basal nitric oxide activity causes albuminuria. Diabetes. 2011;60:572\u20136.","journal-title":"Diabetes"},{"key":"551_CR16","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952\u201361.","journal-title":"N Engl J Med"},{"key":"551_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4103\/0971-5916.90991","volume":"134","author":"R Anantharaman","year":"2011","unstructured":"Anantharaman R, Bhansali A, Bhadada SK, et al. A pilot study on the effect of telmisartan and ramipril on 24\u00a0h blood pressure profile and dipping pattern in type 1 diabetes patients with nephropathy. Indian J Med Res. 2011;134:658\u201363.","journal-title":"Indian J Med Res"},{"key":"551_CR18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1053\/meta.2000.17700","volume":"49","author":"GE Dailey","year":"2000","unstructured":"Dailey GE, Boden GH, Creech RH, et al. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism. 2000;49:1491\u20135.","journal-title":"Metabolism"},{"key":"551_CR19","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/dc12-1940","volume":"36","author":"ER Miller 3rd","year":"2013","unstructured":"Miller ER 3rd, Juraschek SP, Anderson CA et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013;36:1462\u20139.","journal-title":"Diabetes Care"},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000441364","volume":"42","author":"K Lundwall","year":"2015","unstructured":"Lundwall K, Jorneskog G, Jacobson SH, Spaak J. Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial. Am J Nephrol. 2015;42:265\u201373.","journal-title":"Am J Nephrol"},{"key":"551_CR21","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2337\/dc12-0250","volume":"35","author":"MS Miraghajani","year":"2012","unstructured":"Miraghajani MS, Esmaillzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy. Diabetes Care. 2012;35:1981\u20135.","journal-title":"Diabetes Care"},{"key":"551_CR22","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00125-016-4083-4","volume":"59","author":"C Ott","year":"2016","unstructured":"Ott C, Kistner I, Keller M, et al. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59:2579\u201387.","journal-title":"Diabetologia"},{"key":"551_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/00365510802187226","volume":"68","author":"F Persson","year":"2008","unstructured":"Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Investig. 2008;68:731\u20138.","journal-title":"Scand J Clin Lab Investig"},{"key":"551_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1053\/j.jrn.2016.01.013","volume":"26","author":"AS Jimenez-Osorio","year":"2016","unstructured":"Jimenez-Osorio AS, Garcia-Nino WR, Gonzalez-Reyes S, et al. The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr. 2016;26:237\u201344.","journal-title":"J Ren Nutr"},{"key":"551_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829\u201340.","journal-title":"Lancet"},{"key":"551_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907\u201317.","journal-title":"N Engl J Med"},{"key":"551_CR27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","volume":"58","author":"P Ruggenenti","year":"2011","unstructured":"Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58:776\u201383.","journal-title":"Hypertension"},{"key":"551_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2337\/dc12-0706","volume":"36","author":"JB McGill","year":"2013","unstructured":"McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36:237\u201344.","journal-title":"Diabetes Care"},{"key":"551_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/dom.12403","volume":"17","author":"A Kashiwagi","year":"2015","unstructured":"Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17:152\u201360.","journal-title":"Diabetes Obes Metab"},{"key":"551_CR30","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.2337\/dc14-1684","volume":"38","author":"M Laakso","year":"2015","unstructured":"Laakso M, Rosenstock J, Groop PH, et al. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015;38:e15\u20137.","journal-title":"Diabetes Care"},{"key":"551_CR31","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","volume":"59","author":"D Cherney","year":"2016","unstructured":"Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59:1860\u201370.","journal-title":"Diabetologia"},{"key":"551_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.ajkd.2006.11.032","volume":"49","author":"E Ritz","year":"2007","unstructured":"Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194\u2013207.","journal-title":"Am J Kidney Dis"},{"key":"551_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0272-6386(99)70035-1","volume":"34","author":"E Ritz","year":"1999","unstructured":"Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999;34:795\u2013808.","journal-title":"Am J Kidney Dis"},{"key":"551_CR34","doi-asserted-by":"publisher","first-page":"e0144973","DOI":"10.1371\/journal.pone.0144973","volume":"11","author":"A Lampert","year":"2016","unstructured":"Lampert A, Hoffmann GF, Ries M. Ten years after the International Committee of Medical Journal Editors\u2019 Clinical Trial Registration Initiative, one quarter of phase 3 pediatric epilepsy clinical trials still remain unpublished: a cross sectional analysis. PLoS ONE. 2016;11:e0144973.","journal-title":"PLoS ONE"},{"key":"551_CR35","doi-asserted-by":"publisher","unstructured":"Mechler K, Hoffmann GF, Dittmann RW, Ries M. Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished\u2014a cross-sectional analysis. Int J Methods Psychiatr Res. 2017;26(4). doi: https:\/\/doi.org\/10.1002\/mpr.1546.","DOI":"10.1002\/mpr.1546"},{"key":"551_CR36","doi-asserted-by":"publisher","first-page":"e021684","DOI":"10.1136\/bmjopen-2018-021684","volume":"8","author":"T Breil","year":"2018","unstructured":"Breil T, Boettcher M, Hoffmann GF, Ries M. Publication status of completed registered studies in paediatric appendicitis: a cross-sectional analysis. BMJ Open. 2018;8:e021684.","journal-title":"BMJ Open"},{"key":"551_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","volume":"267","author":"K Dickersin","year":"1992","unstructured":"Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374\u20138.","journal-title":"JAMA"},{"key":"551_CR38","doi-asserted-by":"publisher","first-page":"k4383","DOI":"10.1136\/bmj.k4383","volume":"363","author":"B Gyawali","year":"2018","unstructured":"Gyawali B, Shimokata T, Honda K, Ando Y. Reporting harms more transparently in trials of cancer drugs. BMJ. 2018;363:k4383.","journal-title":"BMJ"},{"key":"551_CR39","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49\u201356.","journal-title":"J Nephropharmacol"},{"key":"551_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00125-009-1577-3","volume":"53","author":"E Ritz","year":"2010","unstructured":"Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia. 2010;53:49\u201357.","journal-title":"Diabetologia"},{"key":"551_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.ajkd.2015.08.020","volume":"67","author":"JC Seegmiller","year":"2016","unstructured":"Seegmiller JC, Burns BE, Schinstock CA, Lieske JC, Larson TS. Discordance between iothalamate and iohexol urinary clearances. Am J Kidney Dis. 2016;67:49\u201355.","journal-title":"Am J Kidney Dis"},{"key":"551_CR42","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","volume":"365","author":"IH de Boer","year":"2011","unstructured":"de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366\u201376.","journal-title":"N Engl J Med"},{"key":"551_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","volume":"5","author":"S Zoungas","year":"2017","unstructured":"Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431\u20137.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"551_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"551_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","volume":"133","author":"R Temple","year":"2000","unstructured":"Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455\u201363.","journal-title":"Ann Intern Med"},{"key":"551_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11255-015-1121-y","volume":"48","author":"RM Montero","year":"2016","unstructured":"Montero RM, Covic A, Gnudi L, Goldsmith D. Diabetic nephropathy: what does the future hold? Int Urol Nephrol. 2016;48:99\u2013113.","journal-title":"Int Urol Nephrol"},{"key":"551_CR47","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058\u201370.","journal-title":"Circ Res"},{"key":"551_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/13543784.2017.1293039","volume":"26","author":"V Lacava","year":"2017","unstructured":"Lacava V, Pellicano V, Ferrajolo C, et al. Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opin Investig Drugs. 2017;26:445\u201362.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-018-0551-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-018-0551-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-018-0551-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:28:39Z","timestamp":1724412519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-018-0551-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s13300-018-0551-9","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}